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Abstract
We used the standard comet assay successfully to
generate in vitro dose–response curves under oxic
and hypoxic conditions. We then made mixtures of
cells that had been irradiated with 3 and 9 Gy of X-rays
to simulate two subpopulations in a tumor, but efforts
to accurately detect and quantify the subpopulations
using the standard comet assay were unsuccessful.
Therefore, we investigated a modified comet assay to
determine whether it could be used for measuring
hypoxia in our model systems. U251 MG cells were
grown as subcutaneous tumors in athymic mice; U251
MG and U87 MG cells were grown as intracerebral (i.c.)
tumors in athymic rats. Animals were injected with
RSU 1069, irradiated, and euthanized. Tumors and
normal brains were removed, and the cells were
analyzed using a modified comet assay. Differences
in comet tail moment distributions between tumor and
contralateral normal brain, using tail moments at either
the 25th or 50th percentile in each distribution, were
taken as measures of the degree of tumor hypoxia. For
U251 MG tumors, there was a positive relationship
between tumor size and the degree of hypoxia,
whereas preliminary data from U87 MG i.c. tumors
showed less hypoxia and no apparent relationship
between tumor size and hypoxia.
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Introduction
There is considerable evidence for the existence of hypoxic
cells in many kinds of solid tumors including human brain
tumors [1,2], which include extremely hypoxic cells display-
ing pO2 values <0.5 mmHg and intermediately hypoxic cells
with pO2 values between 0.5 and 20 mm Hg. It has been
known for decades that hypoxic cells are more resistant to
ionizing radiation than their well-oxygenated counterparts
[3]. The radiation dose required to kill hypoxic cells divided
by the radiation dose required to kill the same fraction of
oxic cells defines the oxygen enhancement ratio (OER),
which is typically f3 for extremely hypoxic cells. Cells at
intermediate pO2 have intermediate radiosensitivities, with
OERs between 1 and 3 [4]. In addition to being an obstacle to
attempts to cure brain tumors with radiation, hypoxia can
produce other unwanted effects. Recent clinical studies of
patients with solid tumors elsewhere in the body show a
correlation between tumor hypoxia and metastases [5] and
between hypoxia and tumor progression [6]. Tumor hypoxia,
however, can be exploited for selective cancer treatment, such
as hypoxia-selective cytotoxins and hypoxia-inducible specific
gene therapy [7].
Several methods have been developed for measuring tumor
hypoxia, each of which has its advantages and disadvantages.
These were reviewed by Horsman [8] and included a paired cell
survival assay, polarographic electrode techniques, hypoxic
markers that bind to or are metabolized by hypoxic cells, and
several comet assays.
The comet assay, used in conjunction with ionizing radiation,
permits the detection of hypoxia in solid tumors [9,10]. This
assay measures DNA strand breaks in individual cells, and
ionizing radiation produces about three times more DNA strand
breaks in aerobic cells as compared to hypoxic cells. A method-
ology standardized by Dr. Peggy Olive and colleagues at the
University of British Columbia Cancer Research Center (Van-
couver, Canada) has been used bymany investigators [11–14].
Irradiated cells are embedded in agarose, lysed in an alkaline
solution, electrophoresed for a short time, and then stained with
the fluorescent DNA dye, propidium iodide (PI). During electro-
phoresis, broken DNA migrates more readily into the comet
‘‘tail’’ than does intact DNA. The comet tail moment (TM) is
calculated from the percentage of total DNA in the tail and the
length of the tail, and is typically used to estimate the amount of
DNA damage in individual cells. Hypoxic fraction is calculated
by fitting the histogram of TMs to two normal distributions with
means separated by a factor of 2 to 3 (the OER or anticipated
damage differential due to oxygen). The fraction of measure-
ments in the peak formed by the smaller TMs is defined as the
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hypoxic fraction.We have experienced several problemswith
this analysis in our brain tumor models. The assay is not
sufficiently sensitive to define a small population of hypoxic
cells. The TM distributions from tumor cells are not always fit
well by two normal distributions and, in most tumors, the two
peaks are not easy to distinguish due to the presence of cells
under intermediate oxygen levels in the tumor.
A modified comet assay for measuring hypoxia also has
been developed by Olive [15]. In addition to using radiation to
distinguish between oxic and hypoxic cells, this method uses
the bioreductive drug RSU 1069 [1(2-nitro-1-imidazolyl)-
3-aziridino-2-propanol], which produces DNA crosslinks in
hypoxic cells and DNA strand breaks in oxic cells. DNA
crosslinking in the hypoxic cells prevents broken DNA from
migrating during electrophoresis; this, coupled with the addi-
tional strand breaks produced in oxic cells, makes differ-
ences in the comets from oxic and hypoxic cells more
pronounced.
Here, we report our attempts to measure tumor hypoxia in
human brain tumor models using the standard comet assay
and the modified comet assay. We used the normal brain as
an oxic control for calculating the degree of tumor hypoxia for
intracerebral (i.c.) tumors.
Materials and Methods
Cell Lines and Tumor Models
U251 MG and U87 MG human brain tumor cells were
provided by the Neurological Surgery Tissue Bank at the
University of California, San Francisco. These cells were
originally obtained from patients with glioblastoma multi-
forme. Cells were grown as monolayers in Eagle’s minimal
essential medium with 10% calf fetal serum in a 37jC
incubator. Three xenograft models were used for this study:
U251 MG cells grown as subcutaneous (s.c.) tumors in the
flanks of athymic mice (U251 s.c. tumor); U251 MG cells
grown as i.c. tumors in athymic rats (U251 i.c. tumor), and
U87 MG cells grown as i.c. tumors in athymic rats (U87 i.c.
tumor). The published protocols for generating s.c. and i.c.
tumors were used. Briefly, 5106 cells in 0.1 ml of medium
were injected into the right flanks of athymic mice to produce
U251 s.c. tumors. Intracerebral tumors were generated by
injecting 10 Al of cell suspension containing 2106 U251 MG
cells or 5106 U87 MG cells into the right hemispheres of
athymic rat brains [17].
Induction of Hypoxia In Vitro
To achieve hypoxic conditions in vitro, cells were grown in
glass Petri dishes. Prior to radiation, the dishes were placed
into gas-tight aluminum gassing jigs. The jigs were subjected
to five rounds of evacuation and flushing with either 95% air
and 5% CO2 (oxic conditions) or 95% N2 and 5% CO2
(hypoxic conditions) on a shaking platform. After the last
round of evacuation and flushing, the cells were irradiated
inside the jig. This procedure routinely produces an OER of
f3 when cell survival is the experimental endpoint.
Irradiation and Drug Administration Procedures
For the in vitro studies, log-phase U87 MG cells were
detached from flasks by trypsinization, and single cell sus-
pensions were irradiated on ice at a dose rate of 1.26 Gy/min
using a Philips X-ray machine. For cells irradiated inside the
gassing jigs, the single cell suspension was made immedi-
ately after irradiation.
RSU 1069 was kindly supplied by Drs. I. Stratford and M.
Jaffar at the MRC Radiology Unit (Chilton, UK) and by
Dr. J.S. Sebolt-Leopold at Park Davis Pharmaceutical
Research (Ann Arbor, MI). The drug was dissolved in
Figure 1. Radiation dose response of comet tail moments in U87 MG cells irradiated under oxic conditions (circles) or hypoxic conditions (triangles). Each data
point represents the mean and standard deviation obtained from about 200 comets.
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phosphate-buffered saline (PBS) immediately before use.
Mice and rats received intraperitoneal (i.p.) injections of
RSU 1069 at a dose of 100mg/kg. According to the published
pharmacokinetics [18], after injection, this drug peaks in flank
tumor at about 1 hour and in brain at about 1.5 hours.
Therefore, animals were irradiated whole body with 10 Gy
at these times after i.p. injection of RSU 1069. Immediately
after irradiation, animals were euthanized, the tumor and
normal brain tissues were removed, and they were placed
in cold PBS. Single cell suspensions were prepared by
mincing the tissues in cold PBS and filtering through a 40-
Am nylon mesh. For rats bearing i.c. tumors, brain tissues in
the contralateral hemispheres were removed, placed in cold
PBS, minced, filtered, and used as normal brain controls.
For the standard comet assay, animals received 15 Gy of
whole body irradiation. Immediately after irradiation, tumors
and normal brain tissues were removed, placed in cold PBS,
and processed as above.
Alkaline Comet Assays
Cells were diluted in PBS to a concentration of 4104
cells/ml, and 0.5 ml of single cell suspension was mixed with
1.5 ml of 1% agarose solution and poured onto a clean
microscope slide. Three slides were made for each sample.
The slides were carefully submersed for 1 hour in the dark in
an alkaline lysis solution containing 0.1% sarkosyl, 1 M NaCl,
and 0.03 M NaOH. Slides were washed in 0.03 M NaOH and
2 mM EDTA for 1 hour with two or three changes of wash
solution during the hour. Electrophoresis was carried out at
0.5 V/cm for 24 minutes in wash solution, slides were
neutralized in water for 20 minutes, and then they were
stained for 10 minutes in 2.5 Ag/ml PI.
Figure 2. TM distributions of known mixtures of U87 MG cells irradiated with 3 and 9 Gy of X-rays. Comets were prepared from different mixtures of the two cell
populations and 300 or more comets were analyzed from each mixture. TM distributions were fit with two normal distributions. The relative area under the small TM
peak was calculated as the percentage of 3-Gy irradiated cells in the mixture.
290 Detection of Hypoxia Wang et al.
Neoplasia . Vol. 5, No. 4, 2003
Comets were viewed using a fluorescentmicroscope (Carl
Zeiss,Oberkochen,Germany)and imageswerecapturedwith
aCCDcamera (XillixTechnologies,Vancouver,BC,Canada).
Images were analyzed by a SunSPARCstation 5 (Sun Micro-
systems, Mt. View, CA) using Scilimage software (TNO Insti-
tute of AppliedPhysics, Delft, TheNetherlands). Comets from
three slides of each tumor sample were analyzed.
We compared results from the standard comet assay with
those from the modified comet assay using the U251 s.c.
tumor model. We assumed that the majority of the cells from
normal brain were oxic, and that any shift in the TM distri-
bution towards smaller TMs in the tumor sample was due to
hypoxic cells. The shift in TM was determined at the 25th
percentile (TM25) and the 50th percentile (TM50) levels for
each distribution.
For the i.c. models, normal brain in the contralateral
hemisphere (i.e., the nontumor-bearing side of the rat brain)
served as a normal brain control for each animal. Differences
in TM50 or TM25 between tumor and normal brain were taken
as measures of the degree of tumor hypoxia.
Results
To measure the OER of irradiated U87 MG cells, cells were
subjected to different doses of radiation under oxic or
hypoxic conditions. Following irradiation, the standard comet
assay was performed. The results shown in Figure 1
revealed a linear relationship between radiation dose and
mean TM for both oxic and hypoxic cells. The ratio of the
slopes of these two curves isf3 and provides an estimate of
the OER. To test the accuracy of the comet assay in
detecting a subpopulation of cells with small TMs in a mixed
population of cells that also contained large TMs, we con-
ducted an in vitro experiment using various mixtures of U87
MG cells that had been irradiated with either 3 or 9 Gy. These
doses were selected because they produce a three-fold
Figure 3. TM size distributions of U251 s.c. tumors using the standard comet assay. Comets were prepared immediately after 15 Gy of whole body irradiation.
Three hundred comets were scored from three slides for each tumor sample.
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difference in DNA damage, and should simulate the three-
fold difference in radiation-induced DNA damage between
oxic and hypoxic cells. Following irradiation, the standard
comet assay was performed. All slides were coded with a
designation that was unknown to the observer, and comets
were scored for each mixture. TM distributions for each
mixture were fit with two normal distributions, and the area
under each peak was calculated. This area represents the
percentage of comets in each population (Figure 2). The
calculated percentages for the smaller 3-Gy peak deviated
approximately two-fold from the actual percentages for the
mixtures that contained 5% and 10% of 3-Gy irradiated cells.
In contrast, the fold difference between the calculated and
actual mixtures was much less for the mixtures that con-
tained 20% and 50% of 3-Gy irradiated cells. We also fit
these TM distributions with a Poisson distribution to the TM
peak arising from the 3-Gy dose and a normal distribution to
the peak arising from the 9-Gy dose (data not shown). The
results were similar to those shown in Figure 2; considerable
error was associated with the data obtained from the mix-
tures that contained small percentages of 3-Gy irradiated
cells, whereas less relative error was observed for mixtures
that contained larger percentages of these cells.
We then carried out experiments using U251 s.c. tumors,
comparing results obtained using the standard comet assay
with those obtained using the modified comet assay. Figure 3
shows examples of the TM profiles obtained from various
sizes of tumors using the standard comet assay. Although the
TMdistributionswere broad, none of the profiles revealed two
obvious peaks that would indicate oxic and hypoxic cells.
Wheneither theTM25 or TM50 from13 tumorswasplottedas a
function of tumor size, large variations were obtained among
tumors with similar sizes (Figure 4). Regression analysis
performed on the log tumor size revealed an apparent
decrease in TM50 as a function of tumor size, but the large
estimated variability resulted in a nonsignificant association
between TM50 and tumor size (P= .2). Analysis of the TM25
data produced similar results. Therefore, we were unable to
demonstrate a correlation between either TM25 or TM50 and
tumor size using the standard comet assay.
We repeated the measurements of hypoxia in the U251
s.c. tumor model using the modified comet assay. TM
distributions for normal brain and for various-sized tumors
from one experiment are shown in Figure 5. The TMs from
normal brain cells were much more uniform than those from
tumor cells, and we assumed that the majority of cells in the
normal brain were oxic. Therefore, the broad TM distribu-
tions observed in tumors presumably reflected the presence
of hypoxic cells with smaller TMs. Eleven tumors of various
sizes were studied. When the data were plotted as either
TM25 or TM50 (Figure 6), we obtained reasonably consistent
results. The estimated variability in these data, determined
from regression analysis, was three-fold to four-fold less than
observed for the data derived using the standard comet
assay (Figure 4). Thus, although both sets of data revealed
similar estimates for the decrease in TM50 or TM25 as a
function of tumor size, this apparent relationship was signifi-
cant (P= .03 for the TM50 data) only for the data derived
using the modified comet assay (Figure 6).
We also measured hypoxia in the two i.c. tumor models
using the modified comet assay. TM distributions for U251
i.c. tumors and contralateral normal brains are shown in
Figure 7. When tumor size was small, the contralateral
normal brain displayed a tight TM distribution in which the
majority of cells had relatively large TMs. Again, we assumed
that these TMs represented oxic cells in the tumor. Animals
with larger tumors (e.g., animal 3) exhibited broader TM
distributions for contralateral normal brain. The smaller
TMs in these profiles suggest the presence of hypoxic cells
in the normal brain, which might have been caused by
Figure 4. TM25 (open symbols) and TM50 (closed symbols) for U251 s.c. tumors assayed using the standard comet assay. Each symbol shape represents an
individual tumor; the same symbol means that these tumors were assayed in the same experiment.
292 Detection of Hypoxia Wang et al.
Neoplasia . Vol. 5, No. 4, 2003
compression of the brain by the large tumors. The TM
distributions for tumors were broader than the corresponding
distributions for normal brain and included smaller TMs,
which presumably were due to hypoxic cells. We determined
the TM25 and TM50 for each tumor and for its associated
normal brain and plotted the differences between these
measurements versus tumor size (Figure 8). These differ-
ences were considered to be an index of the amount of
hypoxia in the tumor. Differences between TM25 values for
tumor and its associated normal brain were similar to differ-
ences between TM50 values for tumor and its associated
normal brain. Thus, the sensitivity of the analysis was similar
when either TM25 or TM50 was used for the calculation.
Regression analysis of the TM50 data revealed a positive
correlation between tumor size and amount of hypoxia in
U251 i.c. tumors (P= .01). We also used the samemethod to
measure the degree of hypoxia in four U87 i.c. tumors; the
TM50 data for these tumors are shown along with the TM50
data for U251 i.c. tumors (from Figure 8) in Figure 9. There
was no association between tumor size and hypoxia for U87
i.c. tumors (P= .89). Although the statistical testing for differ-
ences between the two cell lines is limited by the few
observations for U87 i.c. tumors, the test for difference
between the two slopes approached statistical significance
(P= .08).
Discussion
Our laboratory is attempting to develop a hypoxia-specific
therapy for treating human brain tumors. Therefore, we need
an assay that will enable us to monitor changes in hypoxia in
our various brain tumor models. One of the unique features
of the comet assay is its ability to detect DNA damage in
individual cells, which permits the detection of subpopula-
tions in a tumor. Thus, we have investigated the standard
alkaline lysis version of the comet assay using two human
Figure 5. TM distributions of U251 s.c. tumors using the modified comet assay. Mice received an i.p. injection of 100 mg/kg RSU 1069 1 hour before whole body
irradiation with 10 Gy. Comets were prepared immediately after irradiation. Three slides were prepared from each sample; 150 comets were scored for the normal
brain and 300 comets were scored for each tumor sample.
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brain tumor cells, U87 MG and U251 MG. In vitro studies
revealed a linear relationship between radiation dose and
TM, and we obtained the expected OER of f3 (Figure 1).
Therefore, the standard comet assay appeared promising for
our purposes, but a subsequent in vitro experiment showed
that this method was insufficiently sensitive to detect a small
subpopulation of hypoxic cells in a mixed cell population
(Figure 2). Moreover, our in vivo data using the standard
comet assay to detect hypoxia in U251 s.c. tumors failed to
exhibit two peaks representing oxic and hypoxic cells
Figure 6. TM25 (open symbols) and TM50 (closed symbols) for comets obtained from various sizes of U251 s.c. tumors using the modified comet assay. The same
symbol shape means that these tumors were assayed in the same experiment.
Figure 7. TM distributions of U251 i.c. tumors using the modified comet assay. Tumor-bearing rats received i.p. injections of 100 mg/kg RSU 1069 1.5 hours before
whole body irradiation with 10 Gy. Comets were prepared immediately after irradiation. Three slides were prepared from each sample; 300 comets were scored for
each tumor sample and 150 comets were scored for the contralateral normal brain.
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(Figure 3), and they showed large tumor-to-tumor variations
(Figure 4). This result was not entirely unexpected because
cells in solid tumors range from being anoxic to slightly
hypoxic [4]. Therefore, it became obvious that we would
need to employ an analytical method that was not dependent
upon obtaining two peaks in the TM profiles.
Because the modified comet assay had been reported to
amplify the difference between hypoxic cells and oxic cells
[15], we investigated whether it might be suitable for de-
tecting hypoxia in our model systems. We obtained more
consistent results in U251 s.c. tumors, as compared with
results obtained using the standard assay. The TM distribu-
tions from normal brain were tight, and TM distributions from
tumors had greater spread, mostly towards the smaller TMs
that were presumably due to hypoxic cells. We found that
expressing the TM data as percentiles allowed us to com-
pare the amount of hypoxia among tumors, and we found
that the TM25 and TM50 provided equally sensitive measure-
ments of hypoxia. Except for very small tumors, a good
correlation between increasing tumor size and increasing
Figure 8. Tumor hypoxia as calculated by the differences between normal brain and tumor in TM25 (open symbols) or TM50 (closed symbols) as a function of tumor
size. The modified comet assay was used in the U251 i.c. tumor model. Each symbol represents an individual tumor.
Figure 9. Comparison of tumor hypoxia in U87 i.c. tumors (open symbols) and U251 i.c. tumors (closed symbols replotted from Figure 8) as a function of tumor
size. Tumor hypoxia was calculated as the difference between the TM50 of normal brain and tumor.
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hypoxia was obtained using either index in U251 s.c. tumors
(Figure 6). This relationship is consistent with our earlier
observations that the amount of necrosis in U251 s.c. and
i.c. tumors increased with tumor size [16,17], because
necrosis in solid tumors is due to oxygen (and other nutrient)
deprivation.
It was interesting to note that hypoxic cells were detected
in contralateral normal brain tissue when animals had large
i.c. tumors. This may be due to increased intracranial pres-
sure produced by the tumor. We calculated differences in TM
between normal brain and tumor from the same animal. This
results in a good correlation between tumor size and the
degree of tumor hypoxia (Figure 8), similar to what was
observed in U251 s.c. tumors (Figure 6).
The limited data obtained using U87 i.c. tumors indicate
that these tumors have less hypoxia than U251 i.c. tumors at
similar size (Figure 9). Moreover, there does not appear to be
any relationship between hypoxia and tumor size. These
findings corroborate our earlier observations that U87 MG
tumors exhibit less necrosis than correspondingly sizedU251
MG tumors. There are several possible explanations for
these findings. Our in vitro cell survival data show that U87
MG cells are less tolerant to hypoxic conditions than U251
MGcells; approximately 50%of U87MGcells are killedwithin
16 hours when kept under anoxic conditions, whereas no
U251 MG cells were killed under the same conditions (data
not shown). Thus, one might expect to see relatively few
hypoxic cells in U87 tumors at any given time during their
growth. Schultz-Hector et al. [19] measured the distance of
tumor cells from the nearest blood vessel and found higher
vascularity in U87 MG tumors as compared to other tumor
models. These authors also reported that the distance
between tumor cells and blood vessels remained constant
as U87 MG tumors increased in size. This finding indicates
that vessel growth in U87 MG tumors is relatively rapid, and
also may explain the lack of correlation between tumor size
and the degree of tumor hypoxia.
In summary, the modified comet assay worked better in
our model systems than the standard comet assay. We were
able to detect and compare hypoxia levels in the U251 s.c.,
U251 i.c., and U87 i.c. brain tumor models, and the degree of
tumor hypoxia was well represented by differences in either
TM25 or TM50 measurements. Using normal brain as an oxic
control, we found that the degree of tumor hypoxia increased
with increasing tumor size in both U251 s.c. and i.c. tumors.
However, less hypoxia was found in large U87 i.c. tumors as
compared to large U251 i.c. tumors. Our data suggest that
the modified comet assay, when quantified by TM25 or TM50,
is a suitable method for detecting tumor hypoxia in these
model systems.
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